{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T22:29:09Z","timestamp":1786400949662,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"33","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Regional Nouvelle Aquitaine, Foundation Bergoni\u00e9, and La Ligue Contre le Cancer."},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["No. 202008370234"],"award-info":[{"award-number":["No. 202008370234"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011002","name":"National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund","doi-asserted-by":"publisher","award":["82203318"],"award-info":[{"award-number":["82203318"]}],"id":[{"id":"10.13039\/501100011002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.1038\/s41388-026-03875-w","type":"journal-article","created":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T15:14:07Z","timestamp":1783869247000},"page":"3479-3496","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Furin sustains tumor-promoting signals in KRAS- and BRAF-mutated colorectal cancer by engaging the TGF-\u03b21-COX-2 axis in a reciprocal regulatory network"],"prefix":"10.1038","volume":"45","author":[{"given":"Yiyang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Siegfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Pernot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9472-2666","authenticated-orcid":false,"given":"Marta","family":"Martin Bornez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Tejpar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Castanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregoire","family":"Desolneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Evrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Steinmetzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2518-9295","authenticated-orcid":false,"given":"John W. M.","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-0384","authenticated-orcid":false,"given":"Abdel-Majid","family":"Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"3875_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3875_CR2","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467\u201380.","journal-title":"Lancet"},{"key":"3875_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01953-7","volume":"9","author":"Q Li","year":"2024","unstructured":"Li Q, Geng S, Luo H, Wang W, Mo Y-Q, Luo Q, et al. Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy. Sig Transduct Target Ther. 2024;9:1\u201348.","journal-title":"Sig Transduct Target Ther"},{"key":"3875_CR4","doi-asserted-by":"publisher","first-page":"10260","DOI":"10.3390\/ijms221910260","volume":"22","author":"C Stefani","year":"2021","unstructured":"Stefani C, Miricescu D, Stanescu-Spinu I-I, Nica RI, Greabu M, Totan AR, et al. Growth factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now? Int J Mol Sci. 2021;22:10260.","journal-title":"Int J Mol Sci"},{"key":"3875_CR5","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1053\/j.gastro.2023.04.029","volume":"165","author":"L Guo","year":"2023","unstructured":"Guo L, Wang Y, Yang W, Wang C, Guo T, Yang J, et al. Molecular profiling provides clinical insights into targeted and immunotherapies as well as colorectal cancer prognosis. Gastroenterology. 2023;165:414\u201328.e7.","journal-title":"Gastroenterology"},{"key":"3875_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-0116-z","volume":"5","author":"Y-H Xie","year":"2020","unstructured":"Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Sig Transduct Target Ther. 2020;5:1\u201330.","journal-title":"Sig Transduct Target Ther"},{"key":"3875_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173:321\u201337.e10.","journal-title":"Cell"},{"key":"3875_CR8","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.3390\/ijms22105246","volume":"22","author":"F Gaiani","year":"2021","unstructured":"Gaiani F, Marchesi F, Negri F, Greco L, Malesci A, de\u2019Angelis GL, et al. Heterogeneity of colorectal cancer progression: molecular gas and brakes. Int J Mol Sci. 2021;22:5246.","journal-title":"Int J Mol Sci"},{"key":"3875_CR9","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/annonc\/mdr623","volume":"23","author":"D Santini","year":"2012","unstructured":"Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012;23:2313\u20138.","journal-title":"Ann Oncol"},{"key":"3875_CR10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532\u20136.","journal-title":"Nature"},{"key":"3875_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","volume":"11","author":"W De Roock","year":"2010","unstructured":"De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753\u201362.","journal-title":"Lancet Oncol"},{"key":"3875_CR12","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.4251\/wjgo.v13.i12.2129","volume":"13","author":"J Zhi","year":"2021","unstructured":"Zhi J, Jia X-J, Yan J, Wang H-C, Feng B, Xing H-Y, et al. BRAFV600E mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs. World J Gastrointest Oncol. 2021;13:2129\u201348.","journal-title":"World J Gastrointest Oncol"},{"key":"3875_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3892\/br.2020.1303","volume":"13","author":"J Ye","year":"2020","unstructured":"Ye J, Lin M, Zhang C, Zhu X, Li S, Liu H, et al. Tissue gene mutation profiles in patients with colorectal cancer and their clinical implications. Biomed Rep. 2020;13:43\u201348.","journal-title":"Biomed Rep"},{"key":"3875_CR14","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1158\/2159-8290.CD-21-1494","volume":"12","author":"DK Simanshu","year":"2022","unstructured":"Simanshu DK, Morrison DK. A structure is worth a thousand words: new insights for RAS and RAF regulation. Cancer Discov. 2022;12:899\u2013912.","journal-title":"Cancer Discov"},{"key":"3875_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","volume":"37","author":"M Drosten","year":"2020","unstructured":"Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 2020;37:543\u201350.","journal-title":"Cancer Cell"},{"key":"3875_CR16","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/PAS.0b013e31824430d7","volume":"36","author":"RK Pai","year":"2012","unstructured":"Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol. 2012;36:744\u201352.","journal-title":"Am J Surg Pathol"},{"key":"3875_CR17","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3390\/cancers16061215","volume":"16","author":"P Roa","year":"2024","unstructured":"Roa P, Bremer NV, Foglizzo V, Cocco E. Mutations in the serine\/threonine kinase BRAF: oncogenic drivers in solid tumors. Cancers. 2024;16:1215.","journal-title":"Cancers"},{"key":"3875_CR18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S1470-2045(10)70209-6","volume":"12","author":"W De Roock","year":"2011","unstructured":"De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12:594\u2013603.","journal-title":"Lancet Oncol"},{"key":"3875_CR19","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bjc.2013.109","volume":"108","author":"NCT van Grieken","year":"2013","unstructured":"van Grieken NCT, Aoyma T, Chambers PA, Bottomley D, Ward LC, Inam I, et al. KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study. Br J Cancer. 2013;108:1495\u2013501.","journal-title":"Br J Cancer"},{"key":"3875_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ccr.2014.07.007","volume":"26","author":"JR Haling","year":"2014","unstructured":"Haling JR, Sudhamsu J, Yen I, Sideris S, Sandoval W, Phung W, et al. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. Cancer Cell. 2014;26:402\u201313.","journal-title":"Cancer Cell"},{"key":"3875_CR21","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/s41388-021-02175-9","volume":"41","author":"Z He","year":"2022","unstructured":"He Z, Khatib A-M, Creemers JWM. The proprotein convertase furin in cancer: more than an oncogene. Oncogene. 2022;41:1252\u201362.","journal-title":"Oncogene"},{"key":"3875_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.canlet.2019.12.027","volume":"473","author":"G Siegfried","year":"2020","unstructured":"Siegfried G, Descarpentrie J, Evrard S, Khatib A-M. Proprotein convertases: Key players in inflammation-related malignancies and metastasis. Cancer Lett. 2020;473:50\u201361.","journal-title":"Cancer Lett"},{"key":"3875_CR23","doi-asserted-by":"publisher","unstructured":"Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012;11. https:\/\/doi.org\/10.1038\/nrd3699.","DOI":"10.1038\/nrd3699"},{"key":"3875_CR24","doi-asserted-by":"publisher","first-page":"8199","DOI":"10.1074\/jbc.274.12.8199","volume":"274","author":"M Teuchert","year":"1999","unstructured":"Teuchert M, Sch\u00e4fer W, Bergh\u00f6fer S, Hoflack B, Klenk HD, Garten W. Sorting of furin at the trans-Golgi network. Interaction of the cytoplasmic tail sorting signals with AP-1 Golgi-specific assembly proteins. J Biol Chem. 1999;274:8199\u2013207.","journal-title":"J Biol Chem"},{"key":"3875_CR25","doi-asserted-by":"publisher","first-page":"e1073","DOI":"10.1002\/cti2.1073","volume":"8","author":"E Braun","year":"2019","unstructured":"Braun E, Sauter D. Furin-mediated protein processing in infectious diseases and cancer. Clin Transl Immunol. 2019;8:e1073.","journal-title":"Clin Transl Immunol"},{"key":"3875_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nrm934","volume":"3","author":"G Thomas","year":"2002","unstructured":"Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol. 2002;3:753\u201366.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3875_CR27","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1158\/0008-5472.CAN-19-0086","volume":"79","author":"M Tom\u00e9","year":"2019","unstructured":"Tom\u00e9 M, Pappalardo A, Soulet F, L\u00f3pez JJ, Olaizola J, Leger Y, et al. Inactivation of proprotein convertases in T cells inhibits PD-1 expression and creates a favorable immune microenvironment in colorectal cancer. Cancer Res. 2019;79:5008\u201321.","journal-title":"Cancer Res"},{"key":"3875_CR28","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1038\/s41388-020-1238-z","volume":"39","author":"Z He","year":"2020","unstructured":"He Z, Thorrez L, Siegfried G, Meulemans S, Evrard S, Tejpar S, et al. The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer. Oncogene. 2020;39:3571\u201387.","journal-title":"Oncogene"},{"key":"3875_CR29","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/ijc.30714","volume":"141","author":"P Jaaks","year":"2017","unstructured":"Jaaks P, Bernasconi M. The proprotein convertase furin in tumour progression. Int J Cancer. 2017;141:654\u201363.","journal-title":"Int J Cancer"},{"key":"3875_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ccell.2019.08.003","volume":"36","author":"R Jackstadt","year":"2019","unstructured":"Jackstadt R, van Hooff SR, Leach JD, Cortes-Lavaud X, Lohuis JO, Ridgway RA, et al. Epithelial NOTCH signaling rewires the tumor microenvironment of colorectal cancer to drive poor-prognosis subtypes and metastasis. Cancer Cell. 2019;36:319\u201336.e7.","journal-title":"Cancer Cell"},{"key":"3875_CR31","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/cmdc.201700596","volume":"12","author":"T Ivanova","year":"2017","unstructured":"Ivanova T, Hardes K, Kallis S, Dahms SO, Than ME, K\u00fcnzel S, et al. Optimization of substrate-analogue furin inhibitors. ChemMedChem. 2017;12:1953\u201368.","journal-title":"ChemMedChem"},{"key":"3875_CR32","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/carcin\/bgt345","volume":"35","author":"N Scamuffa","year":"2014","unstructured":"Scamuffa N, Sfaxi F, Ma J, Lalou C, Seidah N, Calvo F, et al. Prodomain of the proprotein convertase subtilisin\/kexin Furin (ppFurin) protects from tumor progression and metastasis. Carcinogenesis. 2014;35:528\u201336.","journal-title":"Carcinogenesis"},{"key":"3875_CR33","doi-asserted-by":"publisher","unstructured":"Demoures B, Soulet F, Descarpentrie J, Galeano-Otero I, Sanchez Collado J, Casado M. et al. Repression of apelin Furin cleavage sites provides antimetastatic strategy in colorectal cancer. EMBO Mol Med. 2025. https:\/\/doi.org\/10.1038\/s44321-025-00196-5.","DOI":"10.1038\/s44321-025-00196-5"},{"key":"3875_CR34","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/2326-6066.CIR-15-0241","volume":"4","author":"S Zdanov","year":"2016","unstructured":"Zdanov S, Mandapathil M, Abu Eid R, Adamson-Fadeyi S, Wilson W, Qian J, et al. Mutant KRAS conversion of conventional T cells into regulatory T cells. Cancer Immunol Res. 2016;4:354\u201365.","journal-title":"Cancer Immunol Res"},{"key":"3875_CR35","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massagu\u00e9","year":"2023","unstructured":"Massagu\u00e9 J, Sheppard D. TGF-\u03b2 signaling in health and disease. Cell. 2023;186:4007\u201337.","journal-title":"Cell"},{"key":"3875_CR36","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","volume":"47","author":"MA Coelho","year":"2017","unstructured":"Coelho MA, de Carn\u00e9 Tr\u00e9cesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity. 2017;47:1083\u201399.e6.","journal-title":"Immunity"},{"key":"3875_CR37","unstructured":"Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges | Signal Transduction and Targeted Therapy. https:\/\/www.nature.com\/articles\/s41392-025-02473-8. Accessed 18 Mar2026."},{"key":"3875_CR38","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1039\/D5MD00196J","volume":"16","author":"AE Kassab","year":"2025","unstructured":"Kassab AE. Recent advances in targeting COX-2 for cancer therapy: a review. RSC Med Chem. 2025;16:2974\u20133002.","journal-title":"RSC Med Chem"},{"key":"3875_CR39","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0002-9440(10)63970-3","volume":"158","author":"CM Dubois","year":"2001","unstructured":"Dubois CM, Blanchette F, Laprise MH, Leduc R, Grondin F, Seidah NG. Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. Am J Pathol. 2001;158:305\u201316.","journal-title":"Am J Pathol"},{"key":"3875_CR40","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/cbin.11519","volume":"45","author":"WM de Ara\u00fajo","year":"2021","unstructured":"de Ara\u00fajo WM, Tanaka MN, Lima PHS, de Moraes CF, Leve F, Bastos LG, et al. TGF-\u03b2 acts as a dual regulator of COX-2\/PGE2 tumor promotion depending of its cross-interaction with H-Ras and Wnt\/\u03b2-catenin pathways in colorectal cancer cells. Cell Biol Int. 2021;45:662\u201373.","journal-title":"Cell Biol Int"},{"key":"3875_CR41","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/jcp.1116","volume":"188","author":"F Blanchette","year":"2001","unstructured":"Blanchette F, Rudd P, Grondin F, Attisano L, Dubois CM. Involvement of Smads in TGFbeta1-induced furin (fur) transcription. J Cell Physiol. 2001;188:264\u201373.","journal-title":"J Cell Physiol"},{"key":"3875_CR42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/107327480200902S04","volume":"9","author":"AT Koki","year":"2002","unstructured":"Koki AT, Masferrer JL. Celecoxib: A specific COX-2 inhibitor with anticancer properties. Cancer Control. 2002;9:28\u201335.","journal-title":"Cancer Control"},{"key":"3875_CR43","doi-asserted-by":"publisher","unstructured":"Markosyan N, Kim I-K, Arora C, Quinones-Ware L, Joshi N, Cheng N, et al. Pivotal roles for cancer cell\u2013intrinsic mPGES-1 and autocrine EP4 signaling in suppressing antitumor immunity. JCI Insight. 2024;9 https:\/\/doi.org\/10.1172\/jci.insight.178644.","DOI":"10.1172\/jci.insight.178644"},{"key":"3875_CR44","doi-asserted-by":"publisher","first-page":"12153","DOI":"10.3390\/ijms131012153","volume":"13","author":"AK Arrington","year":"2012","unstructured":"Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, et al. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci. 2012;13:12153\u201368.","journal-title":"Int J Mol Sci"},{"key":"3875_CR45","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1245\/s10434-009-0811-z","volume":"17","author":"AD Siddiqui","year":"2010","unstructured":"Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol. 2010;17:1168\u201376.","journal-title":"Ann Surg Oncol"},{"key":"3875_CR46","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","volume":"5","author":"L Huang","year":"2015","unstructured":"Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5:390\u2013401.","journal-title":"Acta Pharm Sin B"},{"key":"3875_CR47","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1172\/JCI32040","volume":"118","author":"N Scamuffa","year":"2008","unstructured":"Scamuffa N, Siegfried G, Bontemps Y, Ma L, Basak A, Cherel G, et al. Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. J Clin Invest. 2008;118:352\u201363.","journal-title":"J Clin Invest"},{"key":"3875_CR48","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev.cellbio.13.1.513","volume":"13","author":"SM Thomas","year":"1997","unstructured":"Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997;13:513\u2013609.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"3875_CR49","doi-asserted-by":"publisher","first-page":"7906","DOI":"10.1038\/sj.onc.1208160","volume":"23","author":"SJ Parsons","year":"2004","unstructured":"Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene. 2004;23:7906\u20139.","journal-title":"Oncogene"},{"key":"3875_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1593\/neo.131376","volume":"16","author":"DS Potter","year":"2014","unstructured":"Potter DS, Kelly P, Denneny O, Juvin V, Stephens LR, Dive C, et al. BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737. Neoplasia. 2014;16:147\u201357.","journal-title":"Neoplasia"},{"key":"3875_CR51","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ccr.2013.01.023","volume":"23","author":"S Eser","year":"2013","unstructured":"Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, et al. Selective requirement of PI3K\/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell. 2013;23:406\u201320.","journal-title":"Cancer Cell"},{"key":"3875_CR52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2016904118","volume":"118","author":"DK Cheng","year":"2021","unstructured":"Cheng DK, Oni TE, Thalappillil JS, Park Y, Ting H-C, Alagesan B, et al. Oncogenic KRAS engages an RSK1\/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer. Proc Natl Acad Sci USA. 2021;118:e2016904118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3875_CR53","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1053\/j.gastro.2018.10.030","volume":"156","author":"L Wang-Bishop","year":"2019","unstructured":"Wang-Bishop L, Chen Z, Gomaa A, Lockhart AC, Salaria S, Wang J, et al. Inhibition of AURKA reduces proliferation and survival of gastrointestinal cancer cells with activated KRAS by preventing activation of RPS6KB1. Gastroenterology. 2019;156:662\u201375.e7.","journal-title":"Gastroenterology"},{"key":"3875_CR54","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489\u2013501.","journal-title":"Nat Rev Cancer"},{"key":"3875_CR55","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.yexcr.2003.07.009","volume":"291","author":"G Brede","year":"2003","unstructured":"Brede G, Solheim J, Stang E, Prydz H. Mutants of the protein serine kinase PSKH1 disassemble the Golgi apparatus. Exp Cell Res. 2003;291:299\u2013312.","journal-title":"Exp Cell Res"},{"key":"3875_CR56","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.cell.2016.11.035","volume":"167","author":"E Grabocka","year":"2016","unstructured":"Grabocka E, Bar-Sagi D. Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress Granules. Cell. 2016;167:1803\u201313.e12.","journal-title":"Cell"},{"key":"3875_CR57","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejca.2019.01.022","volume":"111","author":"K Kosumi","year":"2019","unstructured":"Kosumi K, Hamada T, Zhang S, Liu L, da Silva A, Koh H, et al. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. Eur J Cancer. 2019;111:82\u201393.","journal-title":"Eur J Cancer"},{"key":"3875_CR58","doi-asserted-by":"publisher","first-page":"E1217","DOI":"10.1210\/jc.2013-4100","volume":"99","author":"L Fang","year":"2014","unstructured":"Fang L, Chang H-M, Cheng J-C, Leung PCK, Sun Y-P. TGF-\u03b21 induces COX-2 expression and PGE2 production in human granulosa cells through Smad signaling pathways. J Clin Endocrinol Metab. 2014;99:E1217\u201326.","journal-title":"J Clin Endocrinol Metab"},{"key":"3875_CR59","doi-asserted-by":"publisher","first-page":"e50701","DOI":"10.1371\/journal.pone.0050701","volume":"7","author":"Y-L Lin","year":"2012","unstructured":"Lin Y-L, Liau J-Y, Yu S-C, Ou D-L, Lin L-I, Tseng L-H, et al. KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells. PLoS One. 2012;7:e50701.","journal-title":"PLoS One"},{"key":"3875_CR60","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1200\/JCO.2009.22.4295","volume":"27","author":"SD Richman","year":"2009","unstructured":"Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009;27:5931\u20137.","journal-title":"J Clin Oncol"},{"key":"3875_CR61","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100\u20133.","journal-title":"Nature"},{"key":"3875_CR62","doi-asserted-by":"publisher","first-page":"9199","DOI":"10.3390\/ijms25179199","volume":"25","author":"AV Ivachtchenko","year":"2024","unstructured":"Ivachtchenko AV, Khvat AV, Shkil DO. Development and Prospects of Furin Inhibitors for Therapeutic Applications. Int J Mol Sci. 2024;25:9199.","journal-title":"Int J Mol Sci"},{"key":"3875_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63479-y","volume":"16","author":"R Klaushofer","year":"2025","unstructured":"Klaushofer R, Bloch K, Eder LS, Marzaro S, Schubert M, B\u00f6ttcher-Friebertsh\u00e4user E, et al. Structural insights into proprotein convertase activation facilitate the engineering of highly specific furin inhibitors. Nat Commun. 2025;16:8206.","journal-title":"Nat Commun"},{"key":"3875_CR64","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","volume":"30","author":"A Singhal","year":"2024","unstructured":"Singhal A, Li BT, O\u2019Reilly EM. Targeting KRAS in cancer. Nat Med. 2024;30:969\u201383.","journal-title":"Nat Med"},{"key":"3875_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07267-4","volume":"15","author":"L Ziane-Chaouche","year":"2024","unstructured":"Ziane-Chaouche L, Raffo-Romero A, Hajjaji N, Kobeissy F, Pinheiro D, Aboulouard S, et al. Inhibition of furin in CAR macrophages directs them toward a proinflammatory phenotype and enhances their antitumor activities. Cell Death Dis. 2024;15:879.","journal-title":"Cell Death Dis"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03875-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03875-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03875-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T22:02:14Z","timestamp":1786399334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03875-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":65,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["3875"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03875-w","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"For human experiments, ethics approval was obtained from the Bergoni\u00e9 Institute, key project [PV2024_071]. Patient consent forms were obtained for all samples at the time of tissue acquisition. The biopsies were de-identified. All animal experiments were conducted in accordance with the guidelines and approved by the Institutional Animal Care and Use Committee of the University of Bordeaux and complied with the protocol approved by the Ethics Committee under the supervision of a trained veterinarian. (Approval No. [APAFIS #51899-2024102315155381 v8]). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}